BTIG Raises DexCom (DXCM) Price Target to $96

BTIG has reaffirmed its Buy rating on DexCom, raising the price target to $96, a 11.65% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:14 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG raised its price target on DexCom, Inc. ($DXCM) to $96 from $90 on October 12, 2026, and rates the stock "Buy".

Since the rating, $DXCM is up 0.1% to date (from the $85.92 close on Oct 12, 2026).

DXCM DexCom, Inc.

$86.04 +29.31% year to date

Daily close · Oct 16, 2026

Key Points

On October 12, 2026, BTIG reiterated its Buy rating on DexCom, Inc. with a new price target of $96, up from $90.
BTIG's $96 price target implies 11.65% upside from DexCom, Inc.'s ($DXCM) current $85.98 share price.
Shares of DexCom recently traded around $85.98, which is about 10.4% below the new price target.
The company reported a trailing twelve-month revenue of approximately $4.97 billion and an EPS of $2.53.

Get $DXCM trade alerts by text

We text you when insiders, Congress or big funds trade $DXCM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated DexCom, Inc. alert may contain errors. Disclosures

BTIG has reaffirmed its Buy rating on DexCom, Inc. (DXCM) and raised its price target from $90 to $96 on October 12, 2026. This target represents a more optimistic outlook for the company, even as shares recently traded around $85.98, about 10.4% below the new target.

Other Institutional Activity in DexCom

Several other institutional investors have held steady with their positions in DexCom. BlackRock Inc. reduced its stake by 720,852 shares, ending with 38,244,137 shares valued at approximately $3.29 billion. Vanguard Capital Management LLC increased its holdings by 187,666 shares, bringing its total to 25,209,752 shares worth about $2.17 billion. Vanguard Portfolio Management LLC also boosted its position by 436,299 shares, ending with 19,656,540 shares valued at roughly $1.69 billion. State Street Corporation added 446,563 shares, totaling 18,380,806 shares worth about $1.58 billion, while Invesco Ltd. significantly increased its stake by 1,616,041 shares, bringing its total to 15,288,133 shares valued at about $1.32 billion.

DexCom, Inc. Stock Down 3.8%

DexCom's shares recently traded at $85.98. This price is notably below the new target of $96 set by BTIG. The stock's performance is worth noting as it sits in the healthcare sector, specifically in the medical devices industry, where it plays a critical role in diabetes management.

12-month forecast

$DXCM price target

DexCom, Inc. daily closes and this analyst's $96 target. Not advice.

Recent Earnings

DexCom reported a trailing twelve-month revenue of about $4.97 billion, showing a year-over-year revenue growth of 13.1%. The company's net margin stands at 20.1%, and it has an impressive return on equity of 38.5%. The next earnings report is scheduled for October 29, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

D 42/100

Reported Apr 30, 2026

Forward outlook
4 target cuts vs 0 raises.
EPS & revenue
EPS beat estimates by 17.0%. Revenue missed estimates by 0.5%.
Profit surprise
EBITDA beat by 5 percent. Operating income beat by 21 percent.
Pre-earnings setup
Bar was high, analysts already very bullish.
Analyst signal
4 target cuts.
Earnings quality
Gross margin up 6.1 points. Operating margin up 8.5 points. Positive free cash flow.

Earnings Call Summary

DexCom delivered first-quarter revenue of $1.19 billion, up fifteen percent year over year, with strong international growth of twenty-six percent. The company achieved record global new patient starts and grew U.S. market share significantly in the type 2 non-insulin segment, driven by the G7 15-day launch and better product algorithms. Management highlighted upcoming announcements including randomized control trial results at the ADA conference and new basal insulin features designed to simplify diabetes treatment.

Guidance DexCom reaffirmed full-year revenue guidance of about $5.18 billion, representing growth of eleven to thirteen percent. The company raised full-year operating profit and EBITDA margin guidance, citing strong cost control and manufacturing improvements. Management expects continued momentum from the G7 15-day product launch and potential coverage expansion for type 2 non-insulin patients later in the year.

Clearly negative report. The company missed important expectations and likely triggers downward revisions.

Insider Buying and Selling at DexCom, Inc.

Recent insider transactions include Chief Financial Officer Jereme M. Sylvain, who sold 3,638 shares at an average price of $83.27 on September 10, 2026. Officer Michael Jon Brown also sold 1,700 shares at $84.04 on September 15, 2026. Lastly, Officer Sadie Stern sold 2,565 shares at an average price of $86.15 on September 28, 2026.

Analysts Set New Price Targets

On October 12, 2026, BTIG maintained its Buy rating on DexCom with a new price target of $96, up from a previous target of $90. This follows several other analysts' positive outlooks, including Truist Securities, which maintained a Buy rating with a target of $102, and TD Cowen, which reiterated a Buy rating with a target of $95.

About DexCom

DexCom, Inc. is a medical device company based in San Diego, California. It specializes in continuous glucose monitoring systems to help manage diabetes and improve metabolic health. With a workforce of around 11,000 employees, DexCom plays a vital role in the healthcare sector, focusing on innovative solutions for diabetes management.

Bottom Line

Investors should watch for the upcoming earnings report on October 29, 2026, which could provide further insights into DexCom's performance. With BTIG's updated price target, the stock's position in relation to that target will be key to monitor in the near term.